These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 1347102

  • 1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.
    Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B.
    Lancet; 1992 Mar 07; 339(8793):594-8. PubMed ID: 1347102
    [Abstract] [Full Text] [Related]

  • 2. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey.
    Knobe KE, Sjörin E, Tengborn LI, Petrini P, Ljung RC.
    Acta Paediatr; 2002 Mar 07; 91(8):910-4. PubMed ID: 12222714
    [Abstract] [Full Text] [Related]

  • 3. Inhibitor development in haemophiliacs: theoretical background and clinical aspects.
    Sultan Y.
    Blood Coagul Fibrinolysis; 1995 Jul 07; 6 Suppl 2():S55-7. PubMed ID: 7495970
    [Abstract] [Full Text] [Related]

  • 4. Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience.
    Mathias M, Liesner R, Hann I, Khair K.
    Haemophilia; 2005 Jul 07; 11(4):340-5. PubMed ID: 16011585
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group.
    Br J Haematol; 2002 Feb 07; 116(2):383-9. PubMed ID: 11841442
    [Abstract] [Full Text] [Related]

  • 6. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I, Hadhri S, El Omri H, Sassi R, Chaabani W, Ennabli S, Skouri H.
    Ann Biol Clin (Paris); 2012 Feb 07; 70(6):659-65. PubMed ID: 23207810
    [Abstract] [Full Text] [Related]

  • 7. [Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature].
    Calvez T, Costagliola D.
    Transfus Clin Biol; 1994 Feb 07; 1(6):427-35. PubMed ID: 7881588
    [Abstract] [Full Text] [Related]

  • 8. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D.
    Thromb Haemost; 1994 May 07; 71(5):544-7. PubMed ID: 8091377
    [Abstract] [Full Text] [Related]

  • 9. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
    Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM.
    Br J Haematol; 2000 Oct 07; 111(1):78-90. PubMed ID: 11091185
    [No Abstract] [Full Text] [Related]

  • 10. The economic impact of factor VIII inhibitors in patients with haemophilia.
    Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J.
    Haemophilia; 2004 Jan 07; 10(1):63-8. PubMed ID: 14962222
    [Abstract] [Full Text] [Related]

  • 11. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ.
    Thromb Haemost; 1997 Sep 07; 78(3):1027-9. PubMed ID: 9308748
    [Abstract] [Full Text] [Related]

  • 12. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M, Kumari M, Shamsi T, Naz A, Farzana T.
    J Coll Physicians Surg Pak; 2012 May 07; 22(5):289-93. PubMed ID: 22538032
    [Abstract] [Full Text] [Related]

  • 13. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M, Warrier I, Rajpurkar M, Lusher JM.
    Haemophilia; 2009 Sep 07; 15(5):1027-31. PubMed ID: 19515028
    [Abstract] [Full Text] [Related]

  • 14. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM, Pourfathollah A, Shooshtari MM, Yazdi ZR.
    Iran J Allergy Asthma Immunol; 2006 Mar 07; 5(1):33-4. PubMed ID: 17242502
    [Abstract] [Full Text] [Related]

  • 15. FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study.
    Balôgôg PN, Tagny CT, Ndoumba A, Mbanya D.
    Int J Lab Hematol; 2014 Oct 07; 36(5):566-70. PubMed ID: 25356499
    [Abstract] [Full Text] [Related]

  • 16. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
    Nilsson IM, Hedner U.
    Scand J Haematol; 1976 May 07; 16(5):369-82. PubMed ID: 951577
    [Abstract] [Full Text] [Related]

  • 17. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.
    Lorenzo JI, López A, Altisent C, Aznar JA.
    Br J Haematol; 2001 Jun 07; 113(3):600-3. PubMed ID: 11380444
    [Abstract] [Full Text] [Related]

  • 18. Development of inhibitors in haemophilia. Ongoing epidemiological study.
    Serban M, Mihailov D, Pop L, Ionita H, Ursu E, Talpos-Niculescu S, Ritli L, Baghiu D, Uscatescu V, Petrovanu C, Stancu P, Savescu D, Cucuianu A, Schramm W.
    Hamostaseologie; 2011 Nov 07; 31 Suppl 1():S20-3. PubMed ID: 22057218
    [Abstract] [Full Text] [Related]

  • 19. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction.
    ElAlfy MS, Tantawy AA, Ahmed MH, Abdin IA.
    Haemophilia; 2000 Nov 07; 6(6):635-8. PubMed ID: 11122388
    [Abstract] [Full Text] [Related]

  • 20. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
    Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L.
    Lancet; 1993 Aug 21; 342(8869):462-4. PubMed ID: 8102429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.